High number of SARS-CoV-2 persistent infections

2 uncovered through genetic analysis of samples from a

3 large community-based surveillance study

4

- 5 Mahan Ghafari^{*,1,2}, Matthew Hall¹, Tanya Golubchik^{1,3}, Daniel Ayoubkhani^{4,5}, Thomas
- 6 House⁶, George MacIntyre-Cockett^{1,7}, Helen Fryer¹, Laura Thomson¹, Anel Nurtay¹, David
- 7 Buck⁷, Angie Green⁷, Amy Trebes⁷, Paolo Piazza⁷, Lorne J Lonie⁷, Ruth Studley⁴, Emma
- 8 Rourke⁴, Darren Smith^{8,9}, Matthew Bashton^{8,9}, Andrew Nelson⁹, Matthew Crown^{8,9}, Clare
- 9 McCann⁹, Gregory R Young^{8,9}, Rui Andre Nunes dos Santos⁹, Zack Richards⁹, Adnan
- 10 Tariq⁹, Roberto Cahuantzi⁴, Wellcome Sanger Institute COVID-19 Surveillance Team^{**},
- 11 COVID-19 Infection Survey Group, The COVID-19 Genomics UK (COG-UK) Consortium^{++,10},
- 12 Jeff Barrett¹¹, Christophe Fraser^{1,7,11}, David Bonsall^{1,7,16}, Ann Sarah Walker^{12,13,14,15}, Katrina
- 13 Lythgoe^{1,2}

14 15

16

- *Corresponding author: mahan.ghafari@ndm.ox.ac.uk
- ¹Big Data Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford
 OX3 7LF, UK.
- 19 ²Department of Biology, University of Oxford, Oxford OX1 3SZ, UK
- ³Sydney Infectious Diseases Institute (Sydney ID), School of Medical Sciences, Faculty of
- 21 ⁴Office for National Statistics, Newport, UK
- 22 Medicine and Health, University of Sydney
- ⁵Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester,
- 24 UK
- ⁶Department of Mathematics, University of Manchester, Manchester, M13 9PL, UK
- ⁷Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Biomedical Research
- 27 Centre, University of Oxford, Old Road Campus, Oxford OX3 7BN, UK.
- ⁸The Hub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of
- 29 Health and Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK
- ⁹Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University,
- 31 Newcastle upon Tyne, NE1 8ST, UK
- 32 10 https://www.cogconsortium.uk
- 33 ¹¹Wellcome Sanger Institute, Cambridge CB10 1SA, UK
- 34 12Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 35 ¹³The National Institute for Health Research Health Protection Research Unit in Healthcare
- 36 Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
- 37 ¹⁴The National Institute for Health Research Oxford Biomedical Research Centre, University of
- 38 Oxford, Oxford, UK
- 39 ¹⁵MRC Clinical Trials Unit at UCL, UCL, London, UK
- 40 ¹⁶Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headington, Oxford
- 41 OX3 9DU, UK

- ^{**}The full list of names is available at https://www.sanger.ac.uk/project/wellcome-sanger-institutecovid-19-surveillance-team/
- 45 **The full list of names and affiliations of COG-UK members is provided in the appendix

Abstract

Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may act as viral reservoirs that could seed future outbreaks ^{1–5}, give rise to highly divergent lineages 6-8, and contribute to cases with post-acute Coronavirus disease 2019 (COVID-19) sequelae (Long Covid) 9,10. However, the population prevalence of persistent infections, their viral load kinetics, and evolutionary dynamics over the course of infections remain largely unknown. We identified 381 infections lasting at least 30 days, of which 54 lasted at least 60 days. These persistently infected individuals had more than 50% higher odds of self-reporting Long Covid compared to the infected controls, and we estimate that 0.09-0.5% of SARS-CoV-2 infections can become persistent and last for at least 60 days. In nearly 70% of the persistent infections we identified, there were long periods during which there were no consensus changes in virus sequences, consistent with prolonged presence of non-replicating virus. Our findings also suggest reinfections with the same major lineage are rare and that many persistent infections are characterised by relapsing viral load dynamics. Furthermore, we found a strong signal for positive selection during persistent infections, with multiple amino acid substitutions in the Spike and ORF1ab genes emerging independently in different individuals, including mutations that are lineage-defining for SARS-CoV-2 variants, at target sites for several monoclonal antibodies, and commonly found in immunocompromised patients ^{11–14}. This work has significant implications for understanding and characterising SARS-CoV-2 infection, epidemiology, and evolution.

Main

 The emergence of highly divergent variants of SARS-CoV-2 has been a defining feature of the COVID-19 pandemic. While the evolutionary origins of these variants are still a matter of speculation, multiple pieces of evidence point to chronic persistent infections as their most likely source ^{5,7,15}. In particular, infections in immunocompromised patients who cannot clear the virus may lead to persistence for months ^{6,7,16,17} or even years ^{8,18} before potentially seeding new outbreaks in the community ³. Persistence of SARS-CoV-2 during chronic infections exposes the viral population to host-immune responses and other selective pressures as a result of treatments over prolonged periods of time. They also release the virus from undergoing the tight population bottlenecks that are characteristic of SARS-CoV-2 transmission ^{19,20}, making the viral population less vulnerable to stochastic genetic drift. These adaptive intrahost changes can lead to elevated evolutionary rates, particularly in key regions of the Spike protein that are often associated with immune escape and elevated rates of transmission ^{13,14}.

Despite the significant public health implications of persistent infections, uncertainty still surrounds how common these infections are among the general population, how

long they last, their potential for adaptive evolution, and their contribution to Long Covid.

In this work, we leveraged genetic, symptom, and epidemiological data from the Office for National Statistics Covid Infection Survey (ONS-CIS) ²¹, an ongoing large scale community-based surveillance study carried out in the UK. We identified individuals with persistent SARS-CoV-2 infection and characterised various aspects of their infection including evolutionary changes in the virus, viral load kinetics, number of reported symptoms, and prevalence of Long Covid.

<u>Identifying persistent infections</u>

We considered more than 100,000 high-quality sequenced samples from the ONS-CIS collected between 2nd November 2020 to 15th August 2022, and representing ~95,000 people living in ~75,000 households across the UK (see **Methods**). Individuals in the survey were typically sampled once a week for the first four weeks of their enrolment, and then monthly thereafter. To identify persistent infections we first limited the dataset to individuals with two or more RT-PCR positive samples with cycle threshold (Ct) values ≤30 (in which sequencing was attempted; a proxy for viral load), taken at least 26 days apart, and where the consensus sequences were of the same major lineages of Alpha, Delta, BA.1 or BA.2 (BA.4 and BA.5 not considered). If those sequences also shared the same rare single nucleotide polymorphisms (SNPs) at one or more sites relative to the major-lineage population-level consensus, we classified them as having a persistent infection.

We defined a rare mutation as one observed in 400 or fewer samples within the entire ONS-CIS dataset, giving a false positive rate of identifying persistent infections of 0-3% depending on the major lineage (see **Methods** and **Supplementary Figure 1**). We note that the rare SNP method provides a conservative estimate for the true number of persistent infections since some persistent infections may not have rare mutations. To further evaluate the robustness of our method in identifying persistent infections, we considered the phylogenetic relationship between the sequences from persistent infections relative to other sequences of the same major lineage that belonged to individuals with only a single sequence within the ONS-CIS dataset. The great majority of sets of sequences identified as belonging to the same persistent infection formed monophyletic groups with strong bootstrap support (**Figure 1a**; see also **Supplementary Figure 2**). However, seven sequences did not group with the other sequence(s) from the same persistent infection. All of these had high Ct values (Ct~30) and poor genome coverage which may explain their lack of clustering on the phylogeny (**Supplementary Figure 2**).

We found 381 persistent infections with sequences spanning at least 26 days, of which 54 spanned at least 56 days, representing nearly 0.07% (54/77,561) of all individuals with one or more sequences (with Ct≤30) of the four major lineages we

investigated in this study (**Figure 1b**; see also **Table 1**). Notably, 9% (2/23), 9% (19/219), and 8% (8/208) of sequences from persistent infections with Alpha, Delta, and BA.1, respectively, were sampled weeks after when the corresponding major lineage has dropped to ≤1% frequency of all the ONS-CIS sequences (**Figure 1c**); the longest infection was with BA.1 and lasted for at least 193 days (see **Figure 1b**).

The actual duration of persistent infections are likely to be at least 3-4 days longer than the time between when the first and last sequenced samples were collected, since it typically takes 3-4 days since the start of infection for viral loads to be sufficiently high to be sequenced (Ct≤30) ^{22,23}, and similarly viral loads will be too low (Ct values too high) to sequence at the tail end of infection. Since individuals were typically sampled weekly during the first four weeks of enrollment, followed by monthly sampling thereafter, it is unsurprising that most persistent infections had observable durations clustering around 30 or 60 days (see **Supplementary Figure 3**).

We found evidence suggestive of transmission from 11 persistently infected individuals: we identified two households each with two members having concurrent persistent infections, and in nine other households, one member tested positive for SARS-CoV-2 by RT-PCR within 10 days of a positive sequenced sample being collected from a persistently infected individual from the same household. As well as being clustered in households, the sequences from the suspected persistently infected source and the recipient had either no consensus nucleotide differences (nine cases) or one consensus nucleotide difference (two cases), consistent with transmission. If these do represent transmission, it is worth noting that none of these persistent infections involved highly divergent sequences relative to their first sequence, and hence these do not provide an example of the emergence and spread of highly divergent lineages.

Identifying reinfections with the same major lineage

We considered a pair of sequences from the same individual to indicate a reinfection if they were sampled at least 26 days apart, had at least one consensus nucleotide difference between the sequenced sampling timepoints, and shared no rare SNPs (see **Methods**). This criterion may overestimate the true number of reinfections as some persistent infections may not have a rare SNP, and within-host evolution can lead to the loss of a rare SNP and/or the gain of other mutations leading to differences in the consensus sequence between the samples. We identified three individuals for which pairs of sequences from different sampling timepoints had no identical rare SNPs and at least one consensus difference, but whose viral load trajectories were consistent with a persistent chronic infection. We therefore excluded these individuals from the reinfection group (see **Supplementary Figure 4**).

Overall, we identified 60 reinfections with the same major lineage (**Table 1**). Of all the cases classed as either persistent infections or reinfections with the same major lineage, 10-15% were classed as reinfections (see **Table 1**), rising to 20-40% if only samples collected at least 56 days apart were included (see **Figure 1b**). This suggests the number of individuals reinfected with the same major lineage is low compared to the number of individuals with persistent infection. Sequences from individuals identified as reinfected, collected at the point of primary infection and reinfection, did not form monophyletic groups and mostly belonged to distantly related subclades, and hence supports our method for identifying reinfections (**Figure 1a**; **Supplementary Figure 2**).

Evidence of non-replicating virus during infection

Of the 381 persistently infected individuals that we identified, nearly 70% (267/381) had a pair of sequenced samples taken at least 26 days apart with no nucleotide differences at the consensus level. This is striking given the between-host within-lineage evolutionary rate of SARS-CoV-2 of ~2 single nucleotide variants (SNVs) per month ^{24–26}. We contrasted the number of consensus nucleotide differences between pairs of samples from persistent infections with 16,000 random pairs of sequences sampled from the complete set of sequenced samples from the ONS-CIS, and with each pair from the same major lineage (**Supplementary Figure 5**). Of these, only 6 pairs had no SNVs (i.e., less than 0.04% of pairs).

Emergence of notable mutations

For all pairs of sequences from each of the persistent infections, we identified mutations for which there was a change in consensus between the two sampling time points. Among the 381 persistently infected individuals, we observed 317 changes in the consensus nucleotide representing 277 unique mutations, and 31 deletions representing 18 unique deletions. Many of these mutations have previously been identified as either lineage-defining mutations for variants of concern or variants of interest ²⁷ (eight mutations and two deletions), recurrent mutations in immunocompromised individuals ^{12–14} (15 mutations and four deletions), or key mutations with antibody escape properties and target sites for various different monoclonal antibodies ^{11,28} (seven mutations) (**Supplementary Table 1**).

We observed several mutations at the same genomic positions in multiple individuals over the course of their persistent infections. For example, three BA.2 infected individuals from different households acquired a mutation at codon position 547 in Spike (**Figure 2**), two of which were the T547K mutation which is a lineage-defining mutation for BA.1, and one the K547T mutation (**Figure 2c**; also see **Supplementary Table 1**). Strikingly, twelve individuals acquired a deletion (ORF1ab: Δ 81-87) in the NSP1 coding region. A similar deletion has previously been

221 observed during the chronic infection of an immunocompromised individual with

cancer ¹⁶, and was associated with lower type I interferon response in infected cells
²⁹. We also identified a persistent infection with BA.1 lasting for at least 133 days
during which 33 unique mutations (23 mutations in ORF1ab, 6 in Spike, 1 in ORF3a,
1 in M, and 2 in ORF7) were observed (see **Supplementary Figure 2**); eleven of the
ORF1ab mutations and all of the mutations in Spike, ORF3a, and ORF7 were
nonsynonymous.

Overall, we observed a strong signal for positive selection in Spike, with nearly nine-fold more nonsynonymous compared to synonymous mutations (**Figure 2b**). With a total of seven nonsynonymous mutations, ORF8 had the highest per base number of nonsynonymous mutations followed by Spike with 61 nonsynonymous mutations.

Persistence with relapsing viral load

Of the 381 persistent infections, 65 had three or more RT-PCR tests taken over the course of their infection. We classified these infections as persistent-relapsing if they had a negative RT-PCR test during the infection (n=20), and the rest as persistent-chronic (n=45) (**Figure 3a,b**). Given the weekly or monthly sampling of individuals enrolled in the ONS-CIS, infections classed as persistent-chronic may have unsampled periods of very low viral burden, meaning the persistent-relapsing category is likely to be an underestimate. Nonetheless, the observation of relapsing viral load dynamics in over 30% of cases is striking given that, in the absence of genetic information, they could have been misidentified as reinfections, depending on the definition used. Of the 27 cases identified as reinfections with three or more RT-PCR tests, all showed relapsing viral load dynamics (**Figure 3c**).

As the sampling strategy of ONS-CIS is based on testing representative individuals across the UK regardless of symptoms, we can estimate the percentage of SARS-CoV-2 infections that are persistent and last for longer than 60 days in the general population. This requires making assumptions about how many persistent infections are missed among ONS-CIS participants due to the monthly (and weekly) sampling. More precisely, estimating the proportion of infections that are persistent depends on the proportion of days the infection has sequenceable virus during the infection (would have Ct≤30 if tested); the fewer the number of days the infection has sequenceable virus, the more likely it is that a persistent infection is be missed. By taking two extreme scenarios for the proportion of days that the virus is sequenceable during persistent infection (0.7 and 0.14; see **Methods**), we estimate that approximately 0.1-0.5% of infections become persistent for 60 days or more.

Difference in viral load and symptoms

For the majority of persistent infections, Ct values (inversely proportional to viral titre ³⁰) were higher at the last sequenced time point compared to the first sequenced time point (**Figure 3d**). For reinfections with the same major lineage, the last

sequenced sample also had higher Ct values than the first, but the magnitude of the difference was smaller compared to persistent infections (**Figure 2d**). In both cases, the rise in Ct value (decrease in viral titre) during infections or between reinfections could be a consequence of host immunity or within-host compartmentalisation. Additionally, the rise in Ct for reinfections could be due to the disproportionate sampling of individuals with older infections, which tend to have lower viral loads, towards the end of an epidemic wave ^{31,32}.

Individuals with persistent infections remained largely asymptomatic during the later stages of infection, with, on average, reporting two fewer symptoms in the last 7 days at the last time of sampling (at which a sequence was obtained) when compared to the first. They also consistently reported very few or no symptoms after the first positive sample (**Figure 3e**). In comparison, individuals reinfected with the same major lineage reported on average only one fewer symptom at the reinfection sampling time point compared to the primary sampling time point (**Figure 3e**).

Prevalence of Long Covid

From February 2021, as well as reporting symptoms, participants were asked if they describe themselves as having Long Covid and still experiencing symptoms more than four weeks after they first had COVID-19 (see **Methods**). We estimated the prevalence of self-reported Long Covid in the persistently infected individuals compared with a control group, accounting for several confounding variables (see **Methods**). In the persistent infection group, 9.0% of respondents (32/354) self-reported Long Covid at their first visit ≥12 weeks since the start of infection, and 7.1% (19/266) reported Long Covid at ≥26 weeks. However, in the control group, only 5.1% (4,976/97,404) reported Long Covid at their first visit ≥12 weeks, and 4.5% (3,261/72,407) reported Long Covid at ≥26 weeks.

Correcting for confounders, we found strong evidence for a 55% higher odds of reporting Long Covid ≥12 weeks post-infection among persistently infected individuals compared to controls (Chi square test with Yates correction ³³ p=0.004 for the unadjusted model, p=0.021 for the adjusted model), but no evidence of a difference for Long Covid ≥26 weeks post-infection (p=0.127 for the unadjusted model, p=0.367 for the adjusted model) (**Table 2**). The lower rate of reporting Long Covid 26 weeks post-infection could be because the majority of the persistent infections we identified lasted for less than 26 weeks, and hence persistence of an infection may no longer be a contributing factor to Long Covid.

Discussion

 We developed a robust approach for identifying persistent SARS-CoV-2 infections in individuals with sequenced samples spanning a month or longer. Of the 381 persistent infections we identified among participants of the ONS-CIS, 54 lasted at

least two months, two over six months, and in some cases the infecting lineage had gone extinct in the general population. In contrast, we only identified 60 reinfections by the same major lineage as the primary infection, suggesting immunity to the same variant remains strong after infection, at least until the lineage has gone extinct.

The large number of persistent infections we uncovered is striking, given the leading hypothesis that many of the variants of concern (VOCs) emerged wholly or partially during long-term chronic infections in immunocompromised individuals ¹. Since the ONS-CIS is a community-based surveillance study, our observations suggest the pool of people in which long-term infections could occur, and hence potential sources of divergent variants, may be much larger than generally thought. We estimate that more than nearly one in a thousand of all infections, and potentially as many as one in 200, may become persistent for at least two months. The harbouring of these persistent infections in the general community may also help explain the early detection of cryptic lineages circulating in wastewaters ^{34,35} long before they spread in the population at large.

In support of the hypothesis that VOCs may emerge during prolonged infections, a number of studies have shown elevated evolutionary rates driven by selection during chronic infections of immunocompromised individuals ^{6–8}. Among the persistently infected individuals we identified, we also found strong evidence for positive selection and parallel evolution, particularly in Spike and ORF1ab. In the most extreme case, we observed one persistent infection with 33 substitutions over a fourmonth period, 20 of which were nonsynonymous.

Potentially more remarkable, however, was our discovery of viral infections exhibiting latent evolutionary dynamics, with no consensus level genome changes for two months or longer. As far as we are aware, this is the first study to demonstrate that decelerated evolutionary rates may be a common outcome of persistent infection. The factors causing these low rates of evolution are unknown, but one possible explanation is infection of long-lived cells ^{36,37} which then seed new outbreaks within the infected individual weeks or months later. Although the relapsing viral load dynamics we found in many of the persistently infected individuals supports this hypothesis, we did not find any consistent pattern between the amount of viral divergence during infection and the lower viral load activity in these individuals.

Intriguingly, individuals with persistent infections report fewer symptoms later in a persistent infection compared to at their first positive sample, or remain asymptomatic throughout infection, but have more than 50% higher odds of Long Covid compared to a control group. Although the link between viral persistence and Long Covid may not be causal, these results suggest persistent infections could be contributing to the pathophysiology of Long Covid ^{10,38}, as also evidenced by the observation of circulating SARS-CoV-2 S1 spike protein in a subset of patients with Long Covid months after first infection ³⁹. The association between persistent

infection and Long Covid does not imply that every persistent infection can lead to Long Covid, only 9% of persistently infected individuals reported having Long Covid, nor does it mean that all cases of Long Covid are due to a persistent infection. Indeed, many other possible mechanisms have been suggested to contribute to Long Covid including autoimmunity/inflammation, organ damage, EBV reactivation, and micro thrombosis (see ref ¹⁰ for a recent review).

Taken together, our observations highlight the continuing importance of community-based genomic surveillance both to monitor the emergence and spread of new variants, but also to gain a fundamental understanding of the natural history and evolution of novel pathogens and their clinical implications for patients.

Methods

ONS COVID-19 Infection Survey

The ONS-CIS is a UK household-based surveillance study in which participant households are approached at random from address lists across the country to provide a representative sample of the population ⁴⁰. All individuals aged two years and older from each household who provide written informed consent provide swab samples (taken by the participant or parent/carer for those under 12 years), regardless of symptoms, and complete a questionnaire at assessments, which occur weekly for the first month in the survey and then monthly. From 26 April 2020 to 31 July 2022, assessments were conducted by study workers visiting each household; from 14 July 2022 onwards assessments were remote, with swabs taken using kits posted to participants and returned by post or courier, and questionnaires completed online or by telephone. Positive swab samples with Ct≤30 were sent for sequencing (see below). For this analysis, we included data from 2nd November 2020 to 15th August 2022, spanning a period from the earliest Alpha to latest Omicron BA.2 sequences within the ONS-CIS dataset.

This work contains statistical data from ONS which is Crown Copyright. The use of the ONS statistical data in this work does not imply the endorsement of the ONS in relation to the interpretation or analysis of the statistical data. This work uses research datasets which may not exactly reproduce National Statistics aggregates.

Sequencing

 From December 2020 onwards sequencing was attempted on all positive samples with Ct≤30; before this date, sequencing was attempted in real-time wherever possible, with some additional retrospective sequencing of stored samples. The vast majority of samples were sequenced on Illumina Novaseq, with a small number using Oxford Nanopore GridION or MINION. One of two protocols were used: either

the ARTIC amplicon protocol ⁴¹ with consensus FASTA sequence files generated using the ARTIC nextflow processing pipeline ⁴², or veSeq, an RNASeq protocol based on a quantitative targeted enrichment strategy ^{19,43} with consensus sequences produced using *shiver* ⁴⁴. During our study period, we identified 94,943 individuals with a single sequence and 5,774 individuals with two or more sequences. Here, we only included sequences with ≥50% genome coverage.

Identifying rare SNPs

An important criterion for determining whether two sequences from the same individual are from the same infection is whether they share a rare single nucleotide polymorphism (SNP). These are defined as SNPs that are shared by fewer than 400 sequences corresponding to each major lineage within the full ONS-CIS dataset (**Supplementary Figure 1**). The thresholds were chosen to maximise the number of persistent infections identified whilst minimising the number of false positives (see below). The major lineages we considered were Alpha (B.1.1.7), Delta (B.1.617.2), Omicron BA.1 and Omicron BA.2, including their sublineages. Approximately 92-98% of all sequences from the four major lineages had a rare SNP relative to the major-lineage population-level consensus.

Identifying reinfections with the same major lineage

Any pair of sequences from the same individual, of the same major lineage, and at least 26 days apart were considered as candidate reinfections. Of these, pairs that had at least one nucleotide difference at the consensus level, and did not share any rare SNPs, were classed as reinfections. Pairs that had no identical rare SNPs, nor any nucleotide differences at the consensus level, were classed as undetermined.

Identifying individuals with persistent infection

We first identified individuals with two or more sequenced samples taken at least 26 days apart. We chose this cutoff because the majority of acutely infected individuals shed the virus for <20 days and no longer than 30 days in the respiratory tract 23,45 . Given the extreme heterogeneity in the shedding profiles during some acute infections 23 , we also considered a more conservative 56-day cutoff for some analyses.

For each identified individual we calculated the number of consensus nucleotide differences per site for all within-individual pairwise combinations of samples (**Supplementary Figure 6**). Only sites where a nucleotide difference could be called were included.

Candidate persistent infections were defined in one of two ways: (1) pairs of sequenced samples that belonged to the same major lineage, and (2) pairs of

sequenced samples where one or both had no defined phylogenetic lineage, but where the genetic distance between them was lower than that required to differentiate two major lineages (see **Supplementary Figure 6**). We assumed pairs belonging to different major lineages were either coinfections or reinfections with two different virus lineages. Only candidate persistent infections were considered in further analysis.

Among the pool of candidate persistent infections, we defined persistent infections as those with sequences sharing one or more rare SNPs at two or more consecutive time points relative to the population-level consensus. A rare SNP is one that is observed in 400 or fewer samples within the entire ONS-CIS dataset.

Determining the false positive rate for persistent infections

For each major lineage we generated a data set of 1,000 randomly paired sequences from different individuals in the ONS-CIS, each sampled at least 26 days apart. We determined the number of these pairs that would have been incorrectly identified as persistent infections as a function of the threshold for determining if a SNP is rare (**Supplementary Figure 1**). Although the total number of persistent infections identified grew as the threshold for determining if a SNP is rare increased, at very high thresholds the rate of false positives was also high. In our study, we chose a threshold of 400 sequences (corresponding to all sequences of the same major lineage within the full ONS-CIS dataset) for all of the major lineages, giving a false positive rate (identifying an infection as persistent when it was not) of 0-3%.

Estimating the prevalence of persistent infections

 Within the ONS-CIS we identified 54 infections that lasted 60 days or more. Comparing this to the number of individuals that had sequenced samples belonging to Alpha, Delta, BA.1 or BA.2, which to a good approximation will be the number of infections of these variants, we identified approximately 54/77,561 (0.07%) infections as persistent for >= 60 days. Since the ONS-CIS is a representative sample of individuals from the general population, we can estimate the percentage of all SARS-CoV-2 infections that became persistent for two months or longer. At one extreme, if all persistent infections have sequenceable virus for only four days per month (assuming viral dynamics similar to one acute infection each month), only 14% of persistent infections would be detected through monthly sampling. Correcting for this, we would estimate the percentage of persistent infections in the general population to be 0.5% (0.07% / 0.14). At the other extreme, if we assume all persistent-chronic infections (70% of persistent infections; see Main text) are detectable through monthly sampling, and the rest have detectable virus for 4 days per month, then we estimate that 74% (70% + 0.14*30%) of persistent infections were identified, giving an estimate of 0.09% (0.07% / 0.74) infections being persistent in the general population.

Phylogenetic analysis

For each of the four major lineages, we chose 600 consensus sequences with at least 95% coverage from the ONS-CIS dataset using weighted random sampling, with each sample of major lineage i collected in week j given a weight $1/n_{ij}$, where n_{ij} is the number of sequences of major lineage i collected during week j ²⁵. These sequences were added as a background set to the collection of all consensus sequences for samples from persistent infections and reinfections. Mapping of each sequence to the Wuhan-Hu-1 reference sequence was already performed by *shiver* and thus a full alignment for each of the four lineages could be constructed using only this.

Maximum likelihood phylogenetic trees were constructed using IQ-TREE 1.6.12 ⁴⁶ using the GTR+gamma substitution model and the ultrafast bootstrap ⁴⁷. Each tree was rooted using the collection dates of the samples and the heuristic residual mean square algorithm in TempEst ⁴⁸. Visualisation used ggtree ⁴⁹.

Comparing viral load activities and symptoms

To quantify the changes in viral load activities during persistent infections, we compared Ct values at the last time point a sequence was obtained to when the first sequence was collected. Similarly, for reinfections, we compared the changes in Ct value between the primary infection and reinfection. We used a paired t-test to calculate p-values in both cases as the distribution of differences in Ct values were normally distributed for both persistent infections (W=0.99, p=0.28) and reinfections (W=0.99, p=0.78) as determined by the Shapiro-Wilk test ⁵⁰.

We also tracked 12 symptoms consistently solicited from all participants at every assessment. Symptoms were fever, weakness/tiredness, diarrhoea, shortness of breath, headache, nausea/vomiting, sore throat, muscle ache, abdominal pain, cough, loss of smell, and loss of taste. At each follow-up assessment, participants were asked whether these 12 symptoms had been present in the past seven days. Symptom discontinuation was defined as the first occurrence of two successive follow-up visits without reporting symptoms. To compare symptom counts during persistent infections and reinfections, we used the paired Wilcoxon test as the distribution of symptom differences is not normally distributed (see **Figure 3d**).

Long Covid analysis

From February 2021, at every assessment, participants were asked "would you describe yourself as having Long Covid, that is, you are still experiencing symptoms more than 4 weeks after you first had COVID-19, that are not explained by something else?". When estimating Long Covid prevalence in this analysis, we

considered the first assessment at least 12 weeks and at least 26 weeks after infection. Our control group comprised all individuals with a positive PCR test and Ct≤30, excluding the persistently infected individuals identified in this study, over the same time span as persistent infections. We also ensured the follow-up from the start of infection to first Long Covid response was similar between persistent infections and controls (see **Table 2**).

In calculating the odds ratio of Long Covid in persistently infected individuals relative to the control group, we accounted for confounding variables such as age at the last birthday, sex, Ct value, calendar date, area deprivation quintile group, presence of self-reported long-term health conditions (binary), vaccination status (unvaccinated or single-vaccinated, fully-vaccinated or booster-vaccinated 14-89 days ago, fully-vaccinated or booster-vaccinated or booster-vaccinated or booster-vaccinated ≥180 days ago), and days from first positive test to Long Covid follow-up response. All variables except the last one were defined at the time of the first positive test. Continuous variables (age, Ct value, calendar date, days to follow-up response) were modelled as restricted cubic splines with a single internal knot at the median of the distribution and boundary knots at the 5th and 95th percentiles. Vaccination status was derived from a combination of CIS and NIMS data for participants in England, and CIS data alone for participants in Wales, Scotland and Northern Ireland.

We were unable to do the Long Covid analysis for the reinfection group due to the low number of participants in this cohort who reported new-onset Long Covid ≥12 weeks or ≥26 weeks after infections.

Funding Statement

The CIS was funded by the Department of Health and Social Care and the UK Health Security Agency with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) (grant code: MC_PC_19027), and Genome Research Limited, operating as the Wellcome Sanger Institute. The authors acknowledge use of data generated through the COVID-19 Genomics Programme funded by the Department of Health and Social Care. ASW is supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (UK HSA) (NIHR200915) and the NIHR Oxford Biomedical Research Centre, and is an NIHR Senior Investigator. TH is supported by the Royal Society and Alan Turing Institute for Data Science and Artificial Intelligence. KAL is supported by the Royal Society and the Wellcome Trust

(107652/Z/15/Z). The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The views expressed are those of the author and not necessarily those of the Department of Health and Social Care or UKHSA.

579580 Data and materials availability

All genomic data have been made publicly available as part of the COVID-19 Genomics UK (COG-UK) Consortium ⁵¹. All other data, excluding personal clinical information on participants, are available in the main text, supplementary materials, or our GitHub repository (https://github.com/mg878/ONS-CIS_analysis).

- Dennehy, J. J., Gupta, R. K., Hanage, W. P., Johnson, M. C. & Peacock, T. P. Where is
 the next SARS-CoV-2 variant of concern? *Lancet* 399, 1938–1939 (2022).
- 591 2. Otto, S. P. *et al.* The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. *Curr. Biol.* **31**, R918–R929 (2021).
- Gonzalez-Reiche, A. S. *et al.* SARS-CoV-2 variants in the making: Sequential intrahost
 evolution and forward transmissions in the context of persistent infections. *medRxiv* 2022.05.25.22275533 (2022) doi:10.1101/2022.05.25.22275533.
- 596 4. Hill, V. *et al.* The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. *Virus Evolution* **8**, veac080 (2022).
- 598 5. Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A. & Weissman, D. B. Investigating the
 evolutionary origins of the first three SARS-CoV-2 variants of concern. *Frontiers in Virology* Section: Diversification and Evolution, (2022).
- 601 6. Choi, B. *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N. Engl. J. Med.* **383**, 2291–2293 (2020).
- 7. Kemp, S. A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature* 592, 277–282 (2021).
- 8. Chaguza, C. *et al.* Accelerated SARS-CoV-2 intrahost evolution leading to distinct
 genotypes during chronic infection. *medRxiv* (2022) doi:10.1101/2022.06.29.22276868.
- Swank, Z. *et al.* Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus
 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin. Infect.* Dis. ciac722 (2022) doi:10.1093/cid/ciac722.
- 10. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
 mechanisms and recommendations. *Nat. Rev. Microbiol.* (2023) doi:10.1038/s41579022-00846-2.
- Starr, T. N. *et al.* Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain
 Reveals Constraints on Folding and ACE2 Binding. *Cell* 182, 1295–1310.e20 (2020).

- 12. McCarthy, K. R. et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive
- antibody escape. *Science* **371**, 1139–1142 (2021).
- 13. Harari, S. *et al.* Drivers of adaptive evolution during chronic SARS-CoV-2 infections.
- 618 Nature Medicine **28**, 1501–1508 (2022).
- 14. Wilkinson, S. A. J. et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients.
- 620 Virus Evol 8, veac050 (2022).
- 15. Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2
- lineage in the UK defined by a novel set of spike mutations. Virological
- 623 https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-
- lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (2020).
- 16. Avanzato, V. A. et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an
- Asymptomatic Immunocompromised Individual with Cancer. *Cell* **183**, 1901–1912.e9
- 627 (2020).
- 17. Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves
- extensive immune escape. Cell Host Microbe 30, 154–162.e5 (2022).
- 18. Nussenblatt, V. et al. Yearlong COVID-19 Infection Reveals Within-Host Evolution of
- 631 SARS-CoV-2 in a Patient With B-Cell Depletion. *J. Infect. Dis.* **225**, 1118–1123 (2022).
- 19. Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372,
- 633 (2021).
- 634 20. Braun, K. M. et al. Acute SARS-CoV-2 infections harbor limited within-host diversity and
- transmit via tight transmission bottlenecks. *PLoS Pathog.* **17**, e1009849 (2021).
- 21. Pouwels, K. B. et al. Community prevalence of SARS-CoV-2 in England from April to
- November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public*
- 638 *Health* **6**, e30–e38 (2021).
- 639 22. Kissler, S. M. et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and
- Unvaccinated Persons. N. Engl. J. Med. **385**, 2489–2491 (2021).
- 23. Jones, T. C. *et al.* Estimating infectiousness throughout SARS-CoV-2 infection course.
- 642 Science **373**, (2021).

- 643 24. Ghafari, M. et al. Purifying selection determines the short-term time dependency of
- evolutionary rates in SARS-CoV-2 and pH1N1 influenza. Preprint at
- 645 https://doi.org/10.1101/2021.07.27.21261148.
- 25. Lythgoe, K. A. et al. Lineage replacement and evolution captured by the United
- 647 Kingdom Covid Infection Survey. *medRxiv* (2022) doi:10.1101/2022.01.05.21268323.
- 26. Neher, R. A. Contributions of adaptation and purifying selection to SARS-CoV-2
- evolution. *Virus Evol* **8**, veac113 (2022).
- 650 27. Hodcroft, E. B. CoVariants: SARS-CoV-2 Mutations and Variants of Interest.
- 651 https://covariants.org/ (2021).
- 652 28. Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro
- 653 studies. Nat. Rev. Microbiol. 21, 112–124 (2023).
- 29. Lin, J.-W. et al. Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant
- that modulates type I interferon response. *Cell Host Microbe* **29**, 489–502.e8 (2021).
- 30. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle
- Threshold Value. Clinical infectious diseases: an official publication of the Infectious
- 658 Diseases Society of America vol. 71 2252–2254 (2020).
- 659 31. Hay, J. A. et al. Estimating epidemiologic dynamics from cross-sectional viral load
- distributions. *Science* **373**, (2021).
- 32. Fryer, H. R. et al. Viral burdens are associated with age and viral variant in a population-
- representative study of SARS-CoV-2 that accounts for time-since-infection related
- sampling bias. Preprint at https://doi.org/10.1101/2022.12.02.518847 (2022).
- 33. Yates, F. Contingency tables involving small numbers and the χ 2 test. Suppl. J. R. Stat.
- 665 Soc. 1, 217 (1934).
- 666 34. Karthikeyan, S. et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant
- 667 transmission. *Nature* **609**, 101–108 (2022).
- 35. Shafer, M. M. et al. Tracing the origin of SARS-CoV-2 Omicron-like Spike sequences
- detected in wastewater. *medRxiv* (2022) doi:10.1101/2022.10.28.22281553.
- 36. Lythgoe, K. A., Gardner, A., Pybus, O. G. & Grove, J. Short-Sighted Virus Evolution and

- a Germline Hypothesis for Chronic Viral Infections. *Trends Microbiol.* **25**, 336–348
- 672 (2017).
- 37. Lythgoe, K. A., Lumley, S. F., Pellis, L., McKeating, J. A. & Matthews, P. C. Estimating
- hepatitis B virus cccDNA persistence in chronic infection. *Virus Evol* **7**, veaa063 (2021).
- 38. Marx, V. Scientists set out to connect the dots on long COVID. Nat. Methods 18, 449-
- 676 453 (2021).
- 39. Schultheiß, C. et al. Liquid biomarkers of macrophage dysregulation and circulating
- spike protein illustrate the biological heterogeneity in patients with post-acute sequelae
- 679 of COVID-19. J. Med. Virol. 95, e28364 (2023).
- 40. Pouwels, K. B. et al. Community prevalence of SARS-CoV-2 in England from April to
- November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public*
- 682 *Health* **6**, e30–e38 (2021).
- 41. COG-UK. COG-UK publication. https://www.protocols.io/workspaces/coguk/publication
- 684 (2020).
- 685 42. Connor Lab. ncov2019-artic-nf. (Github).
- 43. Bonsall, D. et al. A Comprehensive Genomics Solution for HIV Surveillance and Clinical
- 687 Monitoring in Low-Income Settings. *J. Clin. Microbiol.* **58**, (2020).
- 688 44. Wymant, C. et al. Easy and accurate reconstruction of whole HIV genomes from short-
- read sequence data with shiver. *Virus Evol* **4**, vey007 (2018).
- 690 45. Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration
- of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet*
- 692 *Microbe* **2**, e13–e22 (2021).
- 46. Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
- Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 47. Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2:
- Improving the Ultrafast Bootstrap Approximation. *Mol. Biol. Evol.* **35**, 518–522 (2018).
- 48. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal
- structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus*

- 699 Evol **2**, vew007 (2016).
- 700 49. Yu, G., Smith, D. K. & Tsan-Yuk, Z. H. L. ggtree: an R package for visualization and
- annotation of phylogenetic trees with their covariates and other associated data.
- Methods in Ecology and Evolution 8, 28–36 (2017).
- 50. Shapiro, S. S. & Wilk, M. B. An Analysis of Variance Test for Normality (Complete
- 704 Samples). *Biometrika* **52**, 591–611 (1965).
- 705 51. COVID-19 Genomics UK (COG-UK) consortiumcontact@cogconsortium.uk. An
- integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe 1,
- 707 e99-e100 (2020).

709 Tables

710

Table 1: Frequency of persistent infections and reinfections per major lineage.

711 712

Major lineage	Reinfection >26 days	Reinfection >56 days	Persistent infection >26 days	Persistent infections >56 days	%Reinfection >26 days	%Reinfection >56 days
B.1.1.7	7	3	11	3	39%	50%
B.1.617.2	11	4	106	13	9%	24%
BA.1	14	2	97	15	13%	12%
BA.2	28	15	167	23	14%	40%

713

714

Table 2: Prevalence of Long Covid in persistently infected individuals.

715 716

717 Long Covid ≥12 weeks post-infection

Group	n	Long Covid	Median follow- up (IQR*)	Unadjusted OR† (95% CI**)	Adjusted OR (95% CI)
Exposed	356	32 (9.0%)	101 (91-113)	1.27 (1.19-2.47)	1.55 (1.07-2.25)
Control	78,902	4,291 (5.4%)	100 (91-115)	Reference	Reference

718 719

Long Covid ≥26 weeks post-infection

Group	n	Long Covid	Median follow-	Unadjusted OR	Adjusted OR
			up (IQR)	(95% CI)	(95% CI)
Exposed	326	19 (5.8%)	312 (271-390)	1.44 (0.90-2.29)	1.24 (0.77-2.00)
Control	72,608	3,000 (4.1%)	320 (272-384)	Reference	Reference

720 * IQR=interquartile range

721 †OR=odds ratio

722 **CI=confidence interval

Figures 724




Figure 1: Individuals identified with persistent infections and reinfections within the ONS-CIS. (a) Phylogenetic relationship between samples from persistent infections and reinfections with a representative background population of Alpha (see Supplementary Figure 2 for the analysis on the other three major lineages). Dashed lines connect every pair of sequences from the same individual. Pairs from persistent infections cluster closely together while reinfections do not. All sequences from the same individual are given the same colour. (b) Days between the earliest and latest genomic samples from persistent infections and reinfections. Each point represents a single individual. Solid vertical lines show the 26- and 56-day cutoffs. Numbers on the side of each box shows the total counts per category for each major lineage. (c) Total number of sequences in the ONS-CIS per major lineage over time. (d) Timing of persistent infections (black) during the UK epidemic. Some persistent infections can be identified up to weeks after the lineage has been replaced at the population level. The numbers on the side of each box shows the total sequence counts for each category.




Figure 2: Distribution of single nucleotide polymorphisms and non-synonymous vs. synonymous mutations detected during persistent infections. (a) Frequency of mutations that resulted in a SNP change during one or more persistent infections. (b) Number of synonymous (blue) and non-synonymous (orange) mutations per gene during persistent infections. Numbers on each column show the total counts of SNPs in each category of mutations. (c) Description of recurrent mutations and deletions identified during persistent infections. See Supplementary Table 1 for information about other mutations. **None of the recurrent mutations were from households with other infections. †Δ represents a deletion

756

757

758

759

760

761

762

763

764 765

766

767

768

769

770771

772





Figure 3: Comparison of viral load dynamics and number of reported symptoms during persistent infections and reinfections. Viral load trajectories of persistent infections with (a) relapsing and (b) chronic persistent infections and (c) reinfections with at least three PCR tests taken over the course of infection/until reinfection. (d) Change in cycle threshold (Ct) value and (e) total number of symptoms reported between the first and last time points with sequenced samples for all 381 persistent infections (purple) and 60 reinfections (cyan). Viral load at the last time point is significantly lower for persistent infections with Ct value being more than +6.7 (IQR: +3.2,+10.2) units higher at the last time point (paired t-test p<10⁻⁸). The difference is less pronounced for reinfections with +2.5 (IQR: -1.1, +7.4) units difference between primary infection and reinfections (paired t-test p=0.0003). Similarly, persistently infected individuals tend to report fewer number of symptoms at the later stages of their infection compared to reinfections in the last 7 days at the last time point (at which a sequence was obtained) when compared to the first. On average, persistently infected individuals report two more symptoms at the time of their first sequenceable sample (virus samples with a positive Ct≤30) relative to their last sample, with a median of 1 (IQR: 0, 4) fewer reported symptoms (paired Wilcoxon p<10⁻²⁹), while reinfected individuals report only one more symptom at the point of primary infection relative to reinfection, with a median of 0 (IQR: 0, 3) fewer reported symptoms (paired Wilcoxon p=0.005).

Supplementary figures





Threshold value for calling a shared rare SNP

Supplementary Figure 1: Number of persistent infections identified with a shared rare SNP as a function of the threshold for calling a rare SNP. Threshold value of 1 for rare SNPs implies the rare SNP is only found in one sequence of that lineage in the ONS-CIS dataset, excluding sequences from any persistently infected individuals. As the threshold value for calling a rare SNP increases, the number of persistent infections (of any duration) identified (black) increases until at some point the threshold value becomes so high that any individual with two or more sequences of the same major lineage would be identified as a persistent infection based on the rare SNP criterion at which point the false positivity rate (magenta) reaches 100%. At threshold value 400 (vertical dashed line) chosen in this study for identifying persistent infections, the percentage of false positives are 0% for BA.1 and BA.2 and 3% for Alpha and Delta.

a Persistent infections

Reinfections






C Persistent infections

1e-04


Reinfections




790

d Persistent infections

Reinfections





791 792 793

794

795

796

797

798


799


800 801

802

803


Supplementary Figure 2: Phylogenetic relationship between samples from persistent infections and a representative background population per major lineage. Dashed lines connect every pair of sequences from the same individual. All sequences from the same individual are given the same colour. Pairs of sequences for (a) Alpha, (b) Delta, (c) Omicron BA.1, and (d) Omicron BA.2 that belong to persistent infections cluster closely together while reinfections do not. However, some of the sequences in 2 (out of 97) persistent infections with BA.1 and 5 (out of 167) persistent infections with BA.2 have poor bootstrap support (<80) and do not cluster together or cluster in a basal sister relationship. In all of these 7 cases, at least one of the sequences from each individual has a Ct value close to 30 with poor coverage. On the other hand, all sequences that belong to the same individual and have strong bootstrap support (>80) cluster together.







Supplementary Figure 3: Days between all pairs of sequences from the same individual with two or more sequences. Pairs of sequences are classified as (i) pairs with at least one unidentified Pango lineage (green), (ii) pairs with identical major lineage (orange), and (iii) pairs from different major lineages. Bottom panel shows the counts of pairs in each of these three categories for the first 200-day time span (highlighted in a dashed rectangle in the top panel). Pairs include all possible combinations of sequences from the same individual. The number of pairs peaks at the 7-, 30-, and 60-day periods due to the sampling frequency of ONS-CIS (see Methods). Note that pairs with identical major lineage may not necessarily have identical Pango lineages (see Methods).









t > 90 days














Supplementary Figure 4: Viral load dynamics of individuals identified with persistent infections and reinfections stratified by duration and viral activity. Viral load activities of individuals, with 3 or more PCR tests taken during infection/until reinfection, identified as having (a) persistent infections and (b) reinfections with relapsing (left column) and persistent chronic (right column) trajectories. Three reinfections (two occurring in < 60 days and one between 60 to 90 days since first sequence) with persistent chronic viral load dynamics are excluded from the reinfection group as they are deemed potential persistent infections which do not have rare SNPs.

t > 90 days



Supplementary Figure 5: Number of single nucleotide polymorphisms detected in pairs of sequences from persistent infections vs. random pairs from a representative background population. Number of Single Nucleotide Variants (SNVs) per site between all the sequences collected from persistent infections (purple) and random pairs from individuals with only a single sequence within the ONS-CIS (blue) as a function of the number of days between each pair. For each major lineage, a pool of sequences from individuals with only one sequence within the ONS-CIS was sub-sampled and 500 random pairs generated for every 20 additional days between samples. For some major lineages where there were fewer than 500 pairs available beyond a certain time point, all possible random pairs within that 20-day period are used. Solid line and shaded area show the median and interquartile range, respectively, for random pairs over time. Note that the line and shaded area in each graph does not represent the rate of evolution but can be deemed as a measure of lineage diversity as a function of time difference between samples.





Supplementary Figure 6: Pairwise differences between sequences from individuals with two or more sequences. (Left column) Number of single nucleotide polymorphisms (SNPs) between pairs of sequences from each individual with two or more sequences. Pairs include all possible combinations of sequences from the same individual. Vertical dashed line shows the lowest number of SNPs per base for pairs with different major lineages. Any pair with at least one unidentified lineage with a SNP per base smaller than the dashed line is selected as a candidate pair from a persistent infection. Pairs with different major lineages are coloured based on their number of SNPs per base into three groups: (i) pairs with one BA.1 and one BA.2 or BA.4 or BA.5 sequence (orange); (ii) pairs with one BA.2 and one BA.4 or BA.5 sequence (blue); and (iii) pairs with one Omicron (including all BA.x lineages) and one Delta (B.1.617.2), Alpha (B.1.1.7), or B.1.177 sequence (green). (Right column) Proportion of sequences with different number overlapping base pairs. Those with at least one unidentified lineage have a lower number of overlapping base pairs relative to pairs with identifiable lineage (i.e. pairs with identical or different major lineage) mainly due to having lower coverage.

The COVID-19 Genomics UK (COG-UK) consortium 862 863 June 2021 V.1 864 865 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 866 Samples and logistics, Sequencing and analysis, Software and analysis tools, and 867 Visualisation: 868 Dr Samuel C Robson PhD 13,84 869 870 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 871 Samples and logistics, Sequencing and analysis, and Software and analysis tools: Dr Thomas R Connor PhD 11,74 and Prof Nicholas J Loman PhD 43 872 873 874 Leadership and supervision, Metadata curation, Project administration, Samples and 875 logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: Dr Tanya Golubchik PhD 5 876 877 878 Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, 879 Sequencing and analysis, and Visualisation: 088 Dr Rocio T Martinez Nunez PhD 46 881 882 Funding acquisition, Leadership and supervision, Project administration, Samples and 883 logistics, Sequencing and analysis, and Software and analysis tools: Dr David Bonsall PhD 5 884 885 886 Funding acquisition, Leadership and supervision, Project administration, Sequencing and 887 analysis, Software and analysis tools, and Visualisation: Prof Andrew Rambaut DPhil 104 888 889 890 Funding acquisition, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools: 891 892 Dr Luke B Snell MSc, MBBS 12 893 894 Leadership and supervision, Metadata curation, Project administration, Samples and 895 logistics, Software and analysis tools, and Visualisation: Rich Livett MSc 116 896 897 898 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 899 and Samples and logistics: 900 Dr Catherine Ludden PhD ^{20, 70} 901 902 Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, 903 and Sequencing and analysis: Dr Sally Corden PhD 74 and Dr Eleni Nastouli FRCPath 96, 95, 30 904 905 906 Funding acquisition, Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools: 907 Dr Gaia Nebbia PhD, FRCPath ¹² 908

909 Funding acquisition, Leadership and supervision, Project administration, Samples and 910 911 logistics, and Sequencing and analysis: Ian Johnston BSc 116 912 913 914 Leadership and supervision, Metadata curation, Project administration, Samples and 915 logistics, and Sequencing and analysis: Prof Katrina Lythgoe PhD 5, Dr M. Estee Torok FRCP 19, 20 and Prof Ian G Goodfellow PhD 24 916 Leadership and supervision, Metadata curation, Project administration, Samples and 917 918 logistics, and Visualisation: Dr Jacqui A Prieto PhD 97,82 and Dr Kordo Saeed MD, FRCPath 97,83 919 920 921 Leadership and supervision, Metadata curation, Project administration, Sequencing and 922 analysis, and Software and analysis tools: 923 Dr David K Jackson PhD 116 924 925 Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and 926 analysis, and Visualisation: Dr Catherine Houlihan PhD 96,94 927 928 929 Leadership and supervision, Metadata curation, Sequencing and analysis, Software and 930 analysis tools, and Visualisation: Dr Dan Frampton PhD 94, 95 931 932 933 Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, 934 and Software and analysis tools: Dr William L Hamilton PhD 19 and Dr Adam A Witney PhD 41 935 936 937 Funding acquisition, Samples and logistics, Sequencing and analysis, and Visualisation: Dr Giselda Bucca PhD 101 938 939 940 Funding acquisition, Leadership and supervision, Metadata curation, and Project 941 administration: Dr Cassie F Pope PhD^{40, 41} 942 943 944 Funding acquisition, Leadership and supervision, Metadata curation, and Samples and 945 logistics: Dr Catherine Moore PhD 74 946 947 948 Funding acquisition, Leadership and supervision, Metadata curation, and Sequencing and 949 analysis: Prof Emma C Thomson PhD, FRCP 53 950 951 952 Funding acquisition, Leadership and supervision, Project administration, and Samples and 953 logistics: Dr Ewan M Harrison PhD 116, 102 954 955 956 Funding acquisition, Leadership and supervision, Sequencing and analysis, and

- 957 Visualisation: Prof Colin P Smith PhD 101 958 959 960 Leadership and supervision, Metadata curation, Project administration, and Sequencing and 961 analysis: Fiona Rogan BSc 77 962 963 964 Leadership and supervision, Metadata curation, Project administration, and Samples and 965 Shaun M Beckwith MSc ⁶, Abigail Murray Degree ⁶, Dawn Singleton HNC ⁶, Dr Kirstine 966 Eastick PhD, FRCPath ³⁷, Dr Liz A Sheridan PhD ⁹⁸, Paul Randell MSc, PgD ⁹⁹, Dr Leigh M 967 Jackson PhD ¹⁰⁵, Dr Cristina V Ariani PhD ¹¹⁶ and Dr Sónia Gonçalves PhD ¹¹⁶ 968 969 970 Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and 971 analysis: Dr Derek J Fairley PhD 3,77, Prof Matthew W Loose PhD 18 and Joanne Watkins MSc 74 972 973 974 Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation: 975 976 Dr Samuel Moses MD 25, 106 977 978 Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and 979 Dr Sam Nicholls PhD ⁴³, Dr Matthew Bull PhD ⁷⁴ and Dr Roberto Amato PhD ¹¹⁶ 980 981 Leadership and supervision, Project administration, Samples and logistics, and Sequencing 982 983 and analysis: Prof Darren L Smith PhD 36, 65, 66 984 985 986 Leadership and supervision, Sequencing and analysis, Software and analysis tools, and 987 Visualisation: Prof David M Aanensen PhD 14, 116 and Dr Jeffrey C Barrett PhD 116 988 989 Metadata curation, Project administration, Samples and logistics, and Sequencing and 990 991 analysis: Dr Dinesh Aggarwal MRCP^{20, 116, 70}, Dr James G Shepherd MBCHB, MRCP ⁵³, Dr Martin D 992 Curran PhD 71 and Dr Surendra Parmar PhD 71 993 994 995 Metadata curation, Project administration, Sequencing and analysis, and Software and 996 analysis tools: 997 Dr Matthew D Parker PhD ¹⁰⁹ 998 999 Metadata curation, Samples and logistics, Sequencing and analysis, and Software and 1000 analysis tools: Dr Catryn Williams PhD 74 1001
- Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:
 Dr Sharon Glaysher PhD ⁶⁸

1005 1006 Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation: Dr Anthony P Underwood PhD ^{14, 116}, Dr Matthew Bashton PhD ^{36, 65}, Dr Nicole Pacchiarini 1007 PhD ⁷⁴, Dr Katie F Loveson PhD ⁸⁴ and Matthew Byott MSc ^{95, 96} 1008 1009 1010 Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation: 1011 1012 Dr Alessandro M Carabelli PhD 20 1013 Funding acquisition, Leadership and supervision, and Metadata curation: 1014 Dr Kate E Templeton PhD 56, 104 1015 1016 1017 Funding acquisition, Leadership and supervision, and Project administration: Dr Thushan I de Silva PhD ¹⁰⁹, Dr Dennis Wang PhD ¹⁰⁹, Dr Cordelia F Langford PhD ¹¹⁶ and 1018 1019 John Sillitoe BEng 116 1020 1021 Funding acquisition, Leadership and supervision, and Samples and logistics: Prof Rory N Gunson PhD, FRCPath 55 1022 1023 Funding acquisition, Leadership and supervision, and Sequencing and analysis: 1024 Dr Simon Cottrell PhD 74, Dr Justin O'Grady PhD 75, 103 and Prof Dominic Kwiatkowski PhD 1025 116, 108 1026 1027 1028 Leadership and supervision, Metadata curation, and Project administration: 1029 Dr Patrick J Lillie PhD, FRCP ³⁷ 1030 1031 Leadership and supervision, Metadata curation, and Samples and logistics: Dr Nicholas Cortes MBCHB ³³, Dr Nathan Moore MBCHB ³³, Dr Claire Thomas DPhil ³³, 1032 Phillipa J Burns MSc, DipRCPath ³⁷, Dr Tabitha W Mahungu FRCPath ⁸⁰ and Steven Liggett 1033 BSc 86 1034 1035 Leadership and supervision, Metadata curation, and Sequencing and analysis: 1036 Angela H Beckett MSc ^{13,81} and Prof Matthew TG Holden PhD ⁷³ 1037 1038 1039 Leadership and supervision, Project administration, and Samples and logistics: Dr Lisa J Levett PhD ³⁴, Dr Husam Osman PhD ^{70, 35} and Dr Mohammed O Hassan-Ibrahim 1040 PhD, FRCPath 99 1041 1042 1043 Leadership and supervision, Project administration, and Sequencing and analysis: 1044 Dr David A Simpson PhD 77 1045 Leadership and supervision, Samples and logistics, and Sequencing and analysis: 1046 Dr Meera Chand PhD ⁷², Prof Ravi K Gupta PhD ¹⁰², Prof Alistair C Darby PhD ¹⁰⁷ and Prof 1047 Steve Paterson PhD 107 1048 1049 1050 Leadership and supervision, Sequencing and analysis, and Software and analysis tools: Prof Oliver G Pybus DPhil ²³, Dr Erik M Volz PhD ³⁹, Prof Daniela de Angelis PhD ⁵², Prof 1051 David L Robertson PhD ⁵³, Dr Andrew J Page PhD ⁷⁵ and Dr Inigo Martincorena PhD ¹¹⁶ 1052

```
1053
1054
         Leadership and supervision, Sequencing and analysis, and Visualisation:
         Dr Louise Aigrain PhD ^{116} and Dr Andrew R Bassett PhD ^{116}
1055
1056
1057
         Metadata curation, Project administration, and Samples and logistics:
         Dr Nick Wong DPhil, MRCP, FRCPath 50, Dr Yusri Taha MD, PhD 89, Michelle J Erkiert BA 99
1058
         and Dr Michael H Spencer Chapman MBBS 116, 102
1059
1060
1061
         Metadata curation, Project administration, and Sequencing and analysis:
         Dr Rebecca Dewar PhD <sup>56</sup> and Martin P McHugh MSc <sup>56, 111</sup>
1062
1063
1064
         Metadata curation, Project administration, and Software and analysis tools:
         Siddharth Mookerjee MPH <sup>38, 57</sup>
1065
1066
1067
         Metadata curation, Project administration, and Visualisation:
         Stephen Aplin <sup>97</sup>, Matthew Harvey <sup>97</sup>, Thea Sass <sup>97</sup>, Dr Helen Umpleby FRCP <sup>97</sup> and Helen
1068
         Wheeler 97
1069
1070
1071
         Metadata curation, Samples and logistics, and Sequencing and analysis:
1072
         Dr James P McKenna PhD <sup>3</sup>, Dr Ben Warne MRCP <sup>9</sup>, Joshua F Taylor MSc <sup>22</sup>, Yasmin
         Chaudhry BSc <sup>24</sup>, Rhys Izuagbe <sup>24</sup>, Dr Aminu S Jahun PhD <sup>24</sup>, Dr Gregory R Young PhD <sup>36</sup>,
1073
         <sup>65</sup>, Dr Claire McMurray PhD <sup>43</sup>, Dr Clare M McCann PhD <sup>65, 66</sup>, Dr Andrew Nelson PhD <sup>65, 66</sup>
1074
         and Scott Elliott 68
1075
1076
1077
         Metadata curation, Samples and logistics, and Visualisation:
         Hannah Lowe MSc <sup>25</sup>
1078
1079
1080
         Metadata curation, Sequencing and analysis, and Software and analysis tools:
         Dr Anna Price PhD <sup>11</sup>, Matthew R Crown BSc <sup>65</sup>, Dr Sara Rey PhD <sup>74</sup>, Dr Sunando Roy PhD
1081
         <sup>96</sup> and Dr Ben Temperton PhD <sup>105</sup>
1082
1083
1084
1085
         Metadata curation, Sequencing and analysis, and Visualisation:
         Dr Sharif Shaaban PhD ^{73} and Dr Andrew R Hesketh PhD ^{101}
1086
1087
1088
         Project administration, Samples and logistics, and Sequencing and analysis:
         Dr Kenneth G Laing PhD<sup>41</sup>, Dr Irene M Monahan PhD <sup>41</sup> and Dr Judith Heaney PhD <sup>95, 96, 34</sup>
1089
1090
         Project administration, Samples and logistics, and Visualisation:
1091
         Dr Emanuela Pelosi FRCPath <sup>97</sup>, Siona Silviera MSc <sup>97</sup> and Dr Eleri Wilson-Davies MD,
1092
         FRCPath 97
1093
1094
1095
         Samples and logistics, Software and analysis tools, and Visualisation:
         Dr Helen Fryer PhD <sup>5</sup>
1096
1097
1098
         Sequencing and analysis, Software and analysis tools, and Visualization:
         Dr Helen Adams PhD <sup>4</sup>, Dr Louis du Plessis PhD <sup>23</sup>, Dr Rob Johnson PhD <sup>39</sup>, Dr William T
1099
         Harvey PhD <sup>53, 42</sup>, Dr Joseph Hughes PhD <sup>53</sup>, Dr Richard J Orton PhD <sup>53</sup>, Dr Lewis G Spurgin
1100
```

- PhD ⁵⁹, Dr Yann Bourgeois PhD ⁸¹, Dr Chris Ruis PhD ¹⁰², Áine O'Toole MSc ¹⁰⁴, Marina 1101
- Gourtovaia MSc ¹¹⁶ and Dr Theo Sanderson PhD ¹¹⁶ 1102

- Funding acquisition, and Leadership and supervision: 1104
- Dr Christophe Fraser PhD ⁵, Dr Jonathan Edgeworth PhD, FRCPath ¹², Prof Judith Breuer 1105
- MD ^{96, 29}, Dr Stephen L Michell PhD ¹⁰⁵ and Prof John A Todd PhD ¹¹⁵ 1106

1107

- 1108 Funding acquisition, and Project administration:
- Michaela John BSc 10 and Dr David Buck PhD 115 1109

1110

- 1111 Leadership and supervision, and Metadata curation:
- Dr Kavitha Gajee MBBS, FRCPath ³⁷ and Dr Gemma L Kay PhD ⁷⁵ 1112

1113

- 1114 Leadership and supervision, and Project administration:
- Prof Sharon J Peacock PhD ^{20, 70} and David Heyburn ⁷⁴ 1115

1116

- Leadership and supervision, and Samples and logistics: 1117
- Katie Kitchman BSc ³⁷, Prof Alan McNally PhD ^{43, 93}, David T Pritchard MSc, CSci ⁵⁰, Dr 1118
- Samir Dervisevic FRCPath ⁵⁸, Dr Peter Muir PhD ⁷⁰, Dr Esther Robinson PhD ^{70, 35}, Dr Barry 1119
- B Vipond PhD ⁷⁰, Newara A Ramadan MSc, CSci, FIBMS ⁷⁸, Dr Christopher Jeanes MBBS 1120
- ⁹⁰, Danni Weldon BSc ¹¹⁶, Jana Catalan MSc ¹¹⁸ and Neil Jones MSc ¹¹⁸ 1121

1122

- Leadership and supervision, and Sequencing and analysis: 1123
- Dr Ana da Silva Filipe PhD ⁵³, Dr Chris Williams MBBS ⁷⁴, Marc Fuchs BSc ⁷⁷, Dr Julia 1124
- Miskelly PhD ⁷⁷, Dr Aaron R Jeffries PhD ¹⁰⁵, Karen Oliver BSc ¹¹⁶ and Dr Naomi R Park PhD 1125
- 1126

1127

- 1128 Metadata curation, and Samples and logistics:
- Amy Ash BSc ¹, Cherian Koshy MSc, CSci, FIBMS ¹, Magdalena Barrow ⁷, Dr Sarah L 1129
- Buchan PhD ⁷, Dr Anna Mantzouratou PhD ⁷, Dr Gemma Clark PhD ¹⁵, Dr Christopher W 1130
- 1131 Holmes PhD ¹⁶, Sharon Campbell MSc ¹⁷, Thomas Davis MSc ²¹, Ngee Keong Tan MSc ²²,
- 1132 Dr Julianne R Brown PhD ²⁹, Dr Kathryn A Harris PhD ^{29, 2}, Stephen P Kidd MSc ³³, Dr Paul
- R Grant PhD ³⁴, Dr Li Xu-McCrae PhD ³⁵, Dr Alison Cox PhD ^{38, 63}, Pinglawathee Madona 1133
- ^{38, 63}, Dr Marcus Pond PhD ^{38, 63}, Dr Paul A Randell MBBCh ^{38, 63}, Karen T Withell FIBMS ⁴⁸, 1134
- Cheryl Williams MSc 51, Dr Clive Graham MD 60, Rebecca Denton-Smith BSc 62, Emma 1135
- Swindells BSc ⁶², Robyn Turnbull BSc ⁶², Dr Tim J Sloan PhD ⁶⁷, Dr Andrew Bosworth PhD 1136
- ^{70, 35}, Stephanie Hutchings ⁷⁰, Hannah M Pymont MSc ⁷⁰, Dr Anna Casey PhD ⁷⁶, Dr Liz 1137
- Ratcliffe PhD ⁷⁶, Dr Christopher R Jones PhD ^{79, 105}, Dr Bridget A Knight PhD ^{79, 105}, Dr 1138
- Tanzina Haque PhD, FRCPath 80, Dr Jennifer Hart MRCP 80, Dr Dianne Irish-Tavares 1139
- FRCPath ⁸⁰, Eric Witele MSc ⁸⁰, Craig Mower BA ⁸⁶, Louisa K Watson DipHE ⁸⁶, Jennifer 1140
- Collins BSc 89, Gary Eltringham BSc 89, Dorian Crudgington 98, Ben Macklin 98, Prof Miren 1141
- Iturriza-Gomara PhD ¹⁰⁷, Dr Anita O Lucaci PhD ¹⁰⁷ and Dr Patrick C McClure PhD ¹¹³ 1142

- Metadata curation, and Sequencing and analysis: 1144
- Matthew Carlile BSc ¹⁸, Dr Nadine Holmes PhD ¹⁸, Dr Christopher Moore PhD ¹⁸, Dr 1145
- Nathaniel Storey PhD ²⁹, Dr Stefan Rooke PhD ⁷³, Dr Gonzalo Yebra PhD ⁷³, Dr Noel Craine 1146
- DPhil ⁷⁴, Malorie Perry MSc ⁷⁴, Dr Nabil-Fareed Alikhan PhD ⁷⁵, Dr Stephen Bridgett PhD ⁷⁷, 1147
- Kate F Cook MScR 84, Christopher Fearn MSc 84, Dr Salman Goudarzi PhD 84, Prof Ronan A 1148

```
1149 Lyons MD <sup>88</sup>, Dr Thomas Williams MD <sup>104</sup>, Dr Sam T Haldenby PhD <sup>107</sup>, Jillian Durham BSc
```

- 1150 116 and Dr Steven Leonard PhD 116
- 1151
- 1152 Metadata curation, and Software and analysis tools:
- 1153 Robert M Davies MA (Cantab) 116
- 1154
- 1155 Project administration, and Samples and logistics:
- 1156 Dr Rahul Batra MD ¹², Beth Blane BSc ²⁰, Dr Moira J Spyer PhD ^{30, 95, 96}, Perminder Smith
- 1157 MSc ^{32, 112}, Mehmet Yavus ^{85, 109}, Dr Rachel J Williams PhD ⁹⁶, Dr Adhyana IK Mahanama
- 1158 MD ⁹⁷, Dr Buddhini Samaraweera MD ⁹⁷, Sophia T Girgis MSc ¹⁰², Samantha E Hansford
- 1159 CSci ¹⁰⁹, Dr Angie Green PhD ¹¹⁵, Dr Charlotte Beaver PhD ¹¹⁶, Katherine L Bellis ^{116, 102},
- 1160 Matthew J Dorman ¹¹⁶, Sally Kay ¹¹⁶, Liam Prestwood ¹¹⁶ and Dr Shavanthi Rajatileka PhD
- 1161
- 1162
- 1163 Project administration, and Sequencing and analysis:
- 1164 Dr Joshua Quick PhD 43
- 1165
- 1166 Project administration, and Software and analysis tools:
- 1167 Radoslaw Poplawski BSc ⁴³
- 1168
- 1169 Samples and logistics, and Sequencing and analysis:
- 1170 Dr Nicola Reynolds PhD ⁸, Andrew Mack MPhil ¹¹, Dr Arthur Morriss PhD ¹¹, Thomas
- 1171 Whalley BSc ¹¹, Bindi Patel BSc ¹², Dr Iliana Georgana PhD ²⁴, Dr Myra Hosmillo PhD ²⁴,
- 1172 Malte L Pinckert MPhil ²⁴, Dr Joanne Stockton PhD ⁴³, Dr John H Henderson PhD ⁶⁵, Amy
- Hollis HND ⁶⁵, Dr William Stanley PhD ⁶⁵, Dr Wen C Yew PhD ⁶⁵, Dr Richard Myers PhD ⁷²,
- 1174 Dr Alicia Thornton PhD ⁷², Alexander Adams BSc ⁷⁴, Tara Annett BSc ⁷⁴, Dr Hibo Asad PhD
- 1175 ⁷⁴, Alec Birchley MSc ⁷⁴, Jason Coombes BSc ⁷⁴, Johnathan M Evans MSc ⁷⁴, Laia Fina ⁷⁴,
- Bree Gatica-Wilcox MPhil ⁷⁴, Lauren Gilbert ⁷⁴, Lee Graham BSc ⁷⁴, Jessica Hey BSc ⁷⁴,
- 1177 Ember Hilvers MPH ⁷⁴, Sophie Jones MSc ⁷⁴, Hannah Jones ⁷⁴, Sara Kumziene-
- 1178 Summerhayes MSc ⁷⁴, Dr Caoimhe McKerr PhD ⁷⁴, Jessica Powell BSc ⁷⁴, Georgia Pugh ⁷⁴,
- 1179 Sarah Taylor ⁷⁴, Alexander J Trotter MRes ⁷⁵, Charlotte A Williams BSc ⁹⁶, Leanne M
- 1180 Kermack MSc ¹⁰², Benjamin H Foulkes MSc ¹⁰⁹, Marta Gallis MSc ¹⁰⁹, Hailey R Hornsby MSc
- 1181 ¹⁰⁹, Stavroula F Louka MSc ¹⁰⁹, Dr Manoj Pohare PhD ¹⁰⁹, Paige Wolverson MSc ¹⁰⁹, Peijun
- 2 Zhang MSc ¹⁰⁹, George MacIntyre-Cockett BSc ¹¹⁵, Amy Trebes MSc ¹¹⁵, Dr Robin J Moll
- 1183 PhD ¹¹⁶, Lynne Ferguson MSc ¹¹⁷, Dr Emily J Goldstein PhD ¹¹⁷, Dr Alasdair Maclean PhD ¹¹⁷
- 1184 and Dr Rachael Tomb PhD 117
- 1185
- 1186 Samples and logistics, and Software and analysis tools:
- 1187 Dr Igor Starinskij MSc, MRCP ⁵³
- 1188
- 1189 Sequencing and analysis, and Software and analysis tools:
- 1190 Laura Thomson BSc ⁵, Joel Southgate MSc ^{11, 74}, Dr Moritz UG Kraemer DPhil ²³, Dr Jayna
- 1191 Raghwani PhD ²³, Dr Alex E Zarebski PhD ²³, Olivia Boyd MSc ³⁹, Lily Geidelberg MSc ³⁹, Dr
- 1192 Chris J Illingworth PhD 52, Dr Chris Jackson PhD 52, Dr David Pascall PhD 52, Dr Sreenu
- 1193 Vattipally PhD ⁵³, Timothy M Freeman MPhil ¹⁰⁹, Dr Sharon N Hsu PhD ¹⁰⁹, Dr Benjamin B
- 1194 Lindsey MRCP ¹⁰⁹, Dr Keith James PhD ¹¹⁶, Kevin Lewis ¹¹⁶, Gerry Tonkin-Hill ¹¹⁶ and Dr
- 1195 Jaime M Tovar-Corona PhD 116
- 1196

- Sequencing and analysis, and Visualisation: 1197
- MacGregor Cox MSci 20 1198

- 1200 Software and analysis tools, and Visualisation:
- Dr Khalil Abudahab PhD 14, 116, Mirko Menegazzo 14, Ben EW Taylor MEng 14, 116, Dr Corin A 1201
- Yeats PhD ¹⁴, Afrida Mukaddas BTech ⁵³, Derek W Wright MSc ⁵³, Dr Leonardo de Oliveira 1202
- Martins PhD ⁷⁵, Dr Rachel Colquhoun DPhil ¹⁰⁴, Verity Hill ¹⁰⁴, Dr Ben Jackson PhD ¹⁰⁴, Dr JT 1203
- McCrone PhD 104, Dr Nathan Medd PhD 104, Dr Emily Scher PhD 104 and Jon-Paul Keatley 116 1204
- 1205

- 1206 Leadership and supervision:
- 1207 Dr Tanya Curran PhD ³, Dr Sian Morgan FRCPath ¹⁰, Prof Patrick Maxwell PhD ²⁰, Prof Ken
- Smith PhD ²⁰, Dr Sahar Eldirdiri MBBS, MSc, FRCPath ²¹, Anita Kenyon MSc ²¹, Prof Alison 1208
- H Holmes MD ^{38, 57}, Dr James R Price PhD ^{38, 57}, Dr Tim Wyatt PhD ⁶⁹, Dr Alison E Mather 1209
- PhD ⁷⁵, Dr Timofey Skvortsov PhD ⁷⁷ and Prof John A Hartley PhD ⁹⁶ 1210

1211

- 1212 Metadata curation:
- Prof Martyn Guest PhD ¹¹, Dr Christine Kitchen PhD ¹¹, Dr Ian Merrick PhD ¹¹, Robert Munn 1213
- BSc ¹¹, Dr Beatrice Bertolusso Degree ³³, Dr Jessica Lynch MBCHB ³³, Dr Gabrielle Vernet 1214
- MBBS ³³, Stuart Kirk MSc ³⁴, Dr Elizabeth Wastnedge MD ⁵⁶, Dr Rachael Stanley PhD ⁵⁸, 1215
- Giles Idle ⁶⁴, Dr Declan T Bradley PhD ^{69,77}, Dr Jennifer Poyner MD ⁷⁹ and Matilde Mori BSc 1216
- 1217

1218

- 1219 Project administration:
- Owen Jones BSc ¹¹, Victoria Wright BSc ¹⁸, Ellena Brooks MA ²⁰, Carol M Churcher BSc ²⁰, 1220
- Mireille Fragakis HND ²⁰, Dr Katerina Galai PhD ^{20,70}, Dr Andrew Jermy PhD ²⁰, Sarah 1221
- Judges BA ²⁰, Georgina M McManus BSc ²⁰, Kim S Smith ²⁰, Dr Elaine Westwick PhD ²⁰, Dr 1222
- Stephen W Attwood PhD ²³, Dr Frances Bolt PhD ^{38, 57}, Dr Alisha Davies PhD ⁷⁴, Elen De 1223
- Lacy MPH ⁷⁴, Fatima Downing ⁷⁴, Sue Edwards ⁷⁴, Lizzie Meadows MA ⁷⁵, Sarah Jeremiah 1224
- MSc ⁹⁷, Dr Nikki Smith PhD ¹⁰⁹ and Luke Foulser ¹¹⁶ 1225

- 1227 Samples and logistics:
- Dr Themoula Charalampous PhD ^{12, 46}, Amita Patel BSc ¹², Dr Louise Berry PhD ¹⁵, Dr Tim 1228
- Boswell PhD ¹⁵, Dr Vicki M Fleming PhD ¹⁵, Dr Hannah C Howson-Wells PhD ¹⁵, Dr Amelia 1229
- Joseph PhD ¹⁵, Manjinder Khakh ¹⁵, Dr Michelle M Lister PhD ¹⁵, Paul W Bird MSc, MRes ¹⁶, 1230
- Karlie Fallon ¹⁶, Thomas Helmer ¹⁶, Dr Claire L McMurray PhD ¹⁶, Mina Odedra BSc ¹⁶, 1231
- Jessica Shaw BSc ¹⁶, Dr Julian W Tang PhD ¹⁶, Nicholas J Willford MSc ¹⁶, Victoria Blakey 1232
- BSc ¹⁷, Dr Veena Raviprakash MD ¹⁷, Nicola Sheriff BSc ¹⁷, Lesley-Anne Williams BSc ¹⁷, 1233
- Theresa Feltwell MSc ²⁰, Dr Luke Bedford PhD ²⁶, Dr James S Cargill PhD ²⁷, Warwick 1234
- Hughes MSc ²⁷, Dr Jonathan Moore MD ²⁸, Susanne Stonehouse BSc ²⁸, Laura Atkinson 1235
- MSc ²⁹, Jack CD Lee MSc ²⁹, Dr Divya Shah PhD ²⁹, Adela Alcolea-Medina Clinical scientist 1236
- ^{32, 112}, Natasha Ohemeng-Kumi MSc ^{32, 112}, John Ramble MSc ^{32, 112}, Jasveen Sehmi MSc ^{32,}
- 1237
- ¹¹², Dr Rebecca Williams BMBS ³³, Wendy Chatterton MSc ³⁴, Monika Pusok MSc ³⁴, William 1238
- Everson MSc ³⁷, Anibolina Castigador IBMS HCPC ⁴⁴, Emily Macnaughton FRCPath ⁴⁴, Dr 1239
- Kate El Bouzidi MRCP ⁴⁵, Dr Temi Lampejo FRCPath ⁴⁵, Dr Malur Sudhanva FRCPath ⁴⁵, 1240
- Cassie Breen BSc ⁴⁷, Dr Graciela Sluga MD, MSc ⁴⁸, Dr Shazaad SY Ahmad MSc ^{49, 70}, Dr 1241
- Ryan P George PhD ⁴⁹, Dr Nicholas W Machin MSc ^{49, 70}, Debbie Binns BSc ⁵⁰, Victoria 1242
- James BSc ⁵⁰, Dr Rachel Blacow MBCHB ⁵⁵, Dr Lindsay Coupland PhD ⁵⁸, Dr Louise Smith 1243
- PhD ⁵⁹, Dr Edward Barton MD ⁶⁰, Debra Padgett BSc ⁶⁰, Garren Scott BSc ⁶⁰, Dr Aidan Cross 1244

MBCHB ⁶¹, Dr Mariyam Mirfenderesky FRCPath ⁶¹, Jane Greenaway MSc ⁶², Kevin Cole ⁶⁴, 1245 Phillip Clarke ⁶⁷, Nichola Duckworth ⁶⁷, Sarah Walsh ⁶⁷, Kelly Bicknell ⁶⁸, Robert Impey MSc 1246 ⁶⁸, Dr Sarah Wyllie PhD ⁶⁸, Richard Hopes ⁷⁰, Dr Chloe Bishop PhD ⁷², Dr Vicki Chalker PhD 1247 ⁷², Dr Ian Harrison PhD ⁷², Laura Gifford MSc ⁷⁴, Dr Zoltan Molnar PhD ⁷⁷, Dr Cressida 1248 Auckland FRCPath 79, Dr Cariad Evans PhD 85, 109, Dr Kate Johnson PhD 85, 109, Dr David G 1249 Partridge FRCP, FRCPath ^{85, 109}, Dr Mohammad Raza PhD ^{85, 109}, Paul Baker MD ⁸⁶, Prof 1250 Stephen Bonner PhD 86, Sarah Essex 86, Leanne J Murray 86, Andrew I Lawton MSc 87, Dr 1251 Shirelle Burton-Fanning MD 89, Dr Brendan Al Payne MD 89, Dr Sheila Waugh MD 89, Andrea 1252 N Gomes MSc 91, Maimuna Kimuli MSc 91, Darren R Murray MSc 91, Paula Ashfield MSc 92, 1253 Dr Donald Dobie MBCHB ⁹², Dr Fiona Ashford PhD ⁹³, Dr Angus Best PhD ⁹³, Dr Liam 1254 Crawford PhD ⁹³, Dr Nicola Cumley PhD ⁹³, Dr Megan Mayhew PhD ⁹³, Dr Oliver Megram 1255 PhD ⁹³, Dr Jeremy Mirza PhD ⁹³, Dr Emma Moles-Garcia PhD ⁹³, Dr Benita Percival PhD ⁹³, 1256 Megan Driscoll BSc ⁹⁶, Leah Ensell BSc ⁹⁶, Dr Helen L Lowe PhD ⁹⁶, Laurentiu Maftei BSc ⁹⁶, 1257 Matteo Mondani MSc ⁹⁶, Nicola J Chaloner BSc ⁹⁹, Benjamin J Cogger BSc ⁹⁹, Lisa J Easton 1258 MSc ⁹⁹, Hannah Huckson BSc ⁹⁹, Jonathan Lewis MSc, PgD, FIBMS ⁹⁹, Sarah Lowdon BSc 1259 ⁹⁹, Cassandra S Malone MSc ⁹⁹, Florence Munemo BSc ⁹⁹, Manasa Mutingwende MSc ⁹⁹, 1260 Roberto Nicodemi BSc 99, Olga Podplomyk FD 99, Thomas Somassa BSc 99, Dr Andrew 1261 Beggs PhD ¹⁰⁰, Dr Alex Richter PhD ¹⁰⁰, Claire Cormie ¹⁰², Joana Dias MSc ¹⁰², Sally Forrest 1262 BSc ¹⁰², Dr Ellen E Higginson PhD ¹⁰², Mailis Maes MPhil ¹⁰², Jamie Young BSc ¹⁰², Dr Rose 1263 K Davidson PhD ¹⁰³, Kathryn A Jackson MSc ¹⁰⁷, Dr Lance Turtle PhD, MRCP ¹⁰⁷, Dr 1264 Alexander J Keeley MRCP ¹⁰⁹, Prof Jonathan Ball PhD ¹¹³, Timothy Byaruhanga MSc ¹¹³, Dr 1265 Joseph G Chappell PhD ¹¹³, Jayasree Dey MSc ¹¹³, Jack D Hill MSc ¹¹³, Emily J Park MSc 1266 ¹¹³, Arezou Fanaie MSc ¹¹⁴, Rachel A Hilson MSc ¹¹⁴, Geraldine Yaze MSc ¹¹⁴ and Stephanie 1267 Lo 116 1268

Sequencing and analysis:

1269

1270 Safiah Afifi BSc ¹⁰, Robert Beer BSc ¹⁰, Joshua Maksimovic FD ¹⁰, Kathryn McCluggage 1271 Masters ¹⁰, Karla Spellman FD ¹⁰, Catherine Bresner BSc ¹¹, William Fuller BSc ¹¹, Dr Angela 1272 Marchbank BSc ¹¹, Trudy Workman HNC ¹¹, Dr Ekaterina Shelest PhD ^{13, 81}, Dr Johnny 1273 Debebe PhD ¹⁸, Dr Fei Sang PhD ¹⁸, Dr Marina Escalera Zamudio PhD ²³, Dr Sarah Francois 1274 PhD ²³, Bernardo Gutierrez MSc ²³, Dr Tetyana I Vasylyeva DPhil ²³, Dr Flavia Flaviani PhD 1275 ³¹, Dr Manon Ragonnet-Cronin PhD ³⁹, Dr Katherine L Smollett PhD ⁴², Alice Broos BSc ⁵³, 1276 Daniel Mair BSc 53, Jenna Nichols BSc 53, Dr Kyriaki Nomikou PhD 53, Dr Lily Tong PhD 53, 1277 Ioulia Tsatsani MSc 53, Prof Sarah O'Brien PhD 54, Prof Steven Rushton PhD 54, Dr Roy 1278 Sanderson PhD ⁵⁴, Dr Jon Perkins MBCHB ⁵⁵, Seb Cotton MSc ⁵⁶, Abbie Gallagher BSc ⁵⁶, 1279 Dr Elias Allara MD, PhD 70, 102, Clare Pearson MSc 70, 102, Dr David Bibby PhD 72, Dr Gavin 1280 Dabrera PhD ⁷², Dr Nicholas Ellaby PhD ⁷², Dr Eileen Gallagher PhD ⁷², Dr Jonathan Hubb 1281 PhD ⁷², Dr Angie Lackenby PhD ⁷², Dr David Lee PhD ⁷², Nikos Manesis ⁷², Dr Tamyo Mbisa 1282 PhD ⁷², Dr Steven Platt PhD ⁷², Katherine A Twohig ⁷², Dr Mari Morgan PhD ⁷⁴, Alp Aydin 1283 MSci ⁷⁵, David J Baker BEng ⁷⁵, Dr Ebenezer Foster-Nyarko PhD ⁷⁵, Dr Sophie J Prosolek 1284 PhD ⁷⁵, Steven Rudder ⁷⁵, Chris Baxter BSc ⁷⁷, Sílvia F Carvalho MSc ⁷⁷, Dr Deborah Lavin 1285 PhD ⁷⁷, Dr Arun Mariappan PhD ⁷⁷, Dr Clara Radulescu PhD ⁷⁷, Dr Aditi Singh PhD ⁷⁷, Miao 1286 Tang MD ⁷⁷, Helen Morcrette BSc ⁷⁹, Nadua Bayzid BSc ⁹⁶, Marius Cotic MSc ⁹⁶, Dr Carlos E 1287 Balcazar PhD ¹⁰⁴, Dr Michael D Gallagher PhD ¹⁰⁴, Dr Daniel Maloney PhD ¹⁰⁴, Thomas D 1288 Stanton BSc ¹⁰⁴, Dr Kathleen A Williamson PhD ¹⁰⁴, Dr Robin Manley PhD ¹⁰⁵, Michelle L 1289 Michelsen BSc ¹⁰⁵, Dr Christine M Sambles PhD ¹⁰⁵, Dr David J Studholme PhD ¹⁰⁵, Joanna 1290 Warwick-Dugdale BSc ¹⁰⁵, Richard Eccles MSc ¹⁰⁷, Matthew Gemmell MSc ¹⁰⁷, Dr Richard 1291 Gregory PhD ¹⁰⁷, Dr Margaret Hughes PhD ¹⁰⁷, Charlotte Nelson MSc ¹⁰⁷, Dr Lucille Rainbow 1292

PhD ¹⁰⁷, Dr Edith E Vamos PhD ¹⁰⁷, Hermione J Webster BSc ¹⁰⁷, Dr Mark Whitehead PhD ¹⁰⁷, Claudia Wierzbicki BSc ¹⁰⁷, Dr Adrienn Angyal PhD ¹⁰⁹, Dr Luke R Green PhD ¹⁰⁹, Dr Max Whiteley PhD ¹⁰⁹, Emma Betteridge BSc ¹¹⁶, Dr Iraad F Bronner PhD ¹¹⁶, Ben W Farr BSc ¹¹⁶, Scott Goodwin MSc ¹¹⁶, Dr Stefanie V Lensing PhD ¹¹⁶, Shane A McCarthy ^{116, 102}, Dr Michael A Quail PhD ¹¹⁶, Diana Rajan MSc ¹¹⁶, Dr Nicholas M Redshaw PhD ¹¹⁶, Carol Scott ¹¹⁶, Lesley Shirley MSc ¹¹⁶ and Scott AJ Thurston BSc ¹¹⁶

1300 Software and analysis tools:

1299

1342

1343

Dr Will Rowe PhD⁴³, Amy Gaskin MSc ⁷⁴, Dr Thanh Le-Viet PhD ⁷⁵, James Bonfield BSc ¹¹⁶, Jennifier Liddle ¹¹⁶ and Andrew Whitwham BSc ¹¹⁶

1303 1304 1 Barking, Havering and Redbridge University Hospitals NHS Trust, 2 Barts Health NHS Trust, 3 1305 Belfast Health & Social Care Trust, 4 Betsi Cadwaladr University Health Board, 5 Big Data Institute, 1306 Nuffield Department of Medicine, University of Oxford, 6 Blackpool Teaching Hospitals NHS 1307 Foundation Trust, 7 Bournemouth University, 8 Cambridge Stem Cell Institute, University of 1308 Cambridge, 9 Cambridge University Hospitals NHS Foundation Trust, 10 Cardiff and Vale University 1309 Health Board, 11 Cardiff University, 12 Centre for Clinical Infection and Diagnostics Research, 1310 Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 13 Centre for 1311 Enzyme Innovation, University of Portsmouth, 14 Centre for Genomic Pathogen Surveillance, 1312 University of Oxford, 15 Clinical Microbiology Department, Queens Medical Centre, Nottingham 1313 University Hospitals NHS Trust, 16 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 1314 17 County Durham and Darlington NHS Foundation Trust, 18 Deep Seg, School of Life Sciences, 1315 Queens Medical Centre, University of Nottingham, 19 Department of Infectious Diseases and 1316 Microbiology, Cambridge University Hospitals NHS Foundation Trust, 20 Department of Medicine, 1317 University of Cambridge, 21 Department of Microbiology, Kettering General Hospital, 22 Department 1318 of Microbiology, South West London Pathology, 23 Department of Zoology, University of Oxford, 24 1319 Division of Virology, Department of Pathology, University of Cambridge, 25 East Kent Hospitals 1320 University NHS Foundation Trust, 26 East Suffolk and North Essex NHS Foundation Trust, 27 East 1321 Sussex Healthcare NHS Trust, 28 Gateshead Health NHS Foundation Trust, 29 Great Ormond Street 1322 Hospital for Children NHS Foundation Trust, 30 Great Ormond Street Institute of Child Health (GOS ICH), University College London (UCL), 31 Guy's and St. Thomas' Biomedical Research Centre, 32 1323 1324 Guy's and St. Thomas' NHS Foundation Trust, 33 Hampshire Hospitals NHS Foundation Trust, 34 1325 Health Services Laboratories, 35 Heartlands Hospital, Birmingham, 36 Hub for Biotechnology in the 1326 Built Environment, Northumbria University, 37 Hull University Teaching Hospitals NHS Trust, 38 1327 Imperial College Healthcare NHS Trust, 39 Imperial College London, 40 Infection Care Group, St 1328 George's University Hospitals NHS Foundation Trust, 41 Institute for Infection and Immunity, St 1329 George's University of London, 42 Institute of Biodiversity, Animal Health & Comparative Medicine, 43 1330 Institute of Microbiology and Infection, University of Birmingham, 44 Isle of Wight NHS Trust, 45 1331 King's College Hospital NHS Foundation Trust, 46 King's College London, 47 Liverpool Clinical 1332 Laboratories, 48 Maidstone and Tunbridge Wells NHS Trust, 49 Manchester University NHS 1333 Foundation Trust, 50 Microbiology Department, Buckinghamshire Healthcare NHS Trust, 51 1334 Microbiology, Royal Oldham Hospital, 52 MRC Biostatistics Unit, University of Cambridge, 53 MRC-1335 University of Glasgow Centre for Virus Research, 54 Newcastle University, 55 NHS Greater Glasgow 1336 and Clyde, 56 NHS Lothian, 57 NIHR Health Protection Research Unit in HCAI and AMR, Imperial 1337 College London, 58 Norfolk and Norwich University Hospitals NHS Foundation Trust, 59 Norfolk 1338 County Council, 60 North Cumbria Integrated Care NHS Foundation Trust, 61 North Middlesex 1339 University Hospital NHS Trust, 62 North Tees and Hartlepool NHS Foundation Trust, 63 North West 1340 London Pathology, 64 Northumbria Healthcare NHS Foundation Trust, 65 Northumbria University, 66 1341 NU-OMICS, Northumbria University, 67 Path Links, Northern Lincolnshire and Goole NHS Foundation

Trust, 68 Portsmouth Hospitals University NHS Trust, 69 Public Health Agency, Northern Ireland, 70

Public Health England, 71 Public Health England, Cambridge, 72 Public Health England, Colindale,

1344 73 Public Health Scotland, 74 Public Health Wales, 75 Quadram Institute Bioscience, 76 Queen 1345 Elizabeth Hospital, Birmingham, 77 Queen's University Belfast, 78 Royal Brompton and Harefield 1346 Hospitals, 79 Royal Devon and Exeter NHS Foundation Trust, 80 Royal Free London NHS 1347 Foundation Trust, 81 School of Biological Sciences, University of Portsmouth, 82 School of Health 1348 Sciences, University of Southampton, 83 School of Medicine, University of Southampton, 84 School of 1349 Pharmacy & Biomedical Sciences, University of Portsmouth, 85 Sheffield Teaching Hospitals NHS 1350 Foundation Trust, 86 South Tees Hospitals NHS Foundation Trust, 87 Southwest Pathology Services, 1351 88 Swansea University, 89 The Newcastle upon Tyne Hospitals NHS Foundation Trust, 90 The 1352 Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, 91 The Royal Marsden NHS 1353 Foundation Trust, 92 The Royal Wolverhampton NHS Trust, 93 Turnkey Laboratory, University of 1354 Birmingham, 94 University College London Division of Infection and Immunity, 95 University College 1355 London Hospital Advanced Pathogen Diagnostics Unit, 96 University College London Hospitals NHS 1356 Foundation Trust, 97 University Hospital Southampton NHS Foundation Trust, 98 University Hospitals 1357 Dorset NHS Foundation Trust, 99 University Hospitals Sussex NHS Foundation Trust, 100 University 1358 of Birmingham, 101 University of Brighton, 102 University of Cambridge, 103 University of East 1359 Anglia, 104 University of Edinburgh, 105 University of Exeter, 106 University of Kent, 107 University of 1360 Liverpool, 108 University of Oxford, 109 University of Sheffield, 110 University of Southampton, 111 1361 University of St Andrews, 112 Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's 1362 College Hospital NHS Foundation Trust, 113 Virology, School of Life Sciences, Queens Medical 1363 Centre, University of Nottingham, 114 Watford General Hospital, 115 Wellcome Centre for Human 1364 Genetics, Nuffield Department of Medicine, University of Oxford, 116 Wellcome Sanger Institute, 117 1365 West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, 118 Whittington 1366 Health NHS Trust